Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae375 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Jennifer H Ku und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Hospitalization, Vaccine Efficacy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc.
Abstract (Originalsprache)
Background
Influenza causes substantial morbidity, particularly among older individuals. Updated data on the effectiveness of currently licensed vaccines in this population are needed.
Methods
At Kaiser Permanente Southern California, we conducted a retrospective cohort study to evaluate comparative vaccine effectiveness (cVE) of high-dose (HD), adjuvanted, and standard-dose (SD) cell-based influenza vaccines, relative to the SD egg-based vaccine. We included adults aged ≥65 years who received an influenza vaccine between 1 August 2022 and 31 December 2022, with follow-up up to 20 May 2023. Primary outcomes were: (1) influenza-related medical encounters and (2) polymerase chain reaction (PCR)-confirmed influenza-related hospitalization. Adjusted hazard ratios (aHR) were estimated by Cox proportional hazards regression, adjusting for confounders using inverse probability of treatment weighting (IPTW). cVE (%) was calculated as (1—aHR) × 100 when aHR ≤1, and ([1/aHR]—1) × 100 when aHR >1.
Results
Our study population (n = 495 119) was 54.9% female, 46.3% non-Hispanic White, with a median age of 73 years (interquartile range [IQR] 69–79). Characteristics of all groups were well balanced after IPTW. Adjusted cVEs against influenza-related medical encounters in the HD, adjuvanted, and SD cell-based vaccine groups were 9.1% (95% confidence interval [CI]: .9, 16.7), 16.9% (95% CI: 1.7, 29.8), and −6.3 (95% CI: −18.3, 6.9), respectively. Adjusted cVEs against PCR-confirmed hospitalization in the HD, adjuvanted, and SD cell-based groups were 25.1% (95% CI: .2, 43.8), 61.6% (95% CI: 18.1, 82.0), and 26.4% (95% CI: −18.3, 55.7), respectively.
Conclusions
Compared to the SD egg-based vaccine, HD and adjuvanted vaccines conferred additional protection against influenza-related outcomes in the 2022–2023 season in adults ≥65 years. Our results provide real-world evidence of the comparative effectiveness of currently licensed vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Moderna Inc., Cambridge, Massachusetts, USA.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
ORCID-Profile: Jennifer H Ku, Emily Rayens
Förderung
- Moderna, Inc
Zitieren
APA
Ku, J. H., Rayens, E., Sy, L. S., Qian, L., Ackerson, B. K., Luo, Y., Tubert, J. E., Lee, G. S., Modha, P. P., Park, Y., Sun, T., Anderson, E. J., & Tseng, H. F. (2024). Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae375
Vancouver
Ku JH, Rayens E, Sy LS, Qian L, Ackerson BK, Luo Y, et al. Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae375
BibTeX
@article{Ku2024,
author = {Ku, Jennifer H and Rayens, Emily and Sy, Lina S and Qian, Lei and Ackerson, Bradley K and Luo, Yi and Tubert, Julia E and Lee, Gina S and Modha, Punam P and Park, Yoonyoung and Sun, Tianyu and Anderson, Evan J and Tseng, Hung Fu},
title = {Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae375}
}
EUVIMED